Okano Yoshiyuki, Hase Yutaka, Kawajiri Mie, Nishi Yasuaki, Inui Koji, Sakai Norio, Tanaka Yoko, Takatori Kazuhiko, Kajiwara Masahiro, Yamano Tsunekazu
Department of Pediatrics, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
Pediatr Res. 2004 Nov;56(5):714-9. doi: 10.1203/01.PDR.0000141520.06524.51. Epub 2004 Aug 19.
Tetrahydrobiopterin (BH4)-responsive phenylalanine hydroxylase (PAH) deficiency is characterized by reduction of blood phenylalanine level after a BH4-loading test. Most cases of BH4-responsive PAH deficiency include mild phenylketonuria (PKU) or mild hyperphenylalaninemia (HPA), but not all patients with mild PKU respond to BH4. We performed the phenylalanine breath test as reliable method to determine the BH4 responsiveness. Phenylalanine breath test quantitatively measures the conversion of L-[1-13C] phenylalanine to 13CO2 and is a noninvasive and rapid test. Twenty Japanese patients with HPA were examined with a dose of 10 mg/kg of 13C-phenylalanine with or without a dose of 10 mg . kg(-1) . d(-1) of BH4 for 3 d. The phenylalanine breath test [cumulative recovery rate (CRR)] could distinguish control subjects (15.4 +/- 1.5%); heterozygotes (10.3 +/- 1.0%); and mild HPA (2.74%), mild PKU (1.13 +/- 0.14%), and classical PKU patients (0.29 +/- 0.14%). The genotypes in mild PKU cases were compound heterozygotes with mild (L52S, R241C, R408Q) and severe mutations, whereas a mild HPA case was homozygote of R241C. CRR correlated inversely with pretreatment phenylalanine levels, indicating the gene dosage effects on PKU. BH4 loading increased CRR from 1.13 +/- 0.14 to 2.95 +/- 1.14% (2.6-fold) in mild PKU and from 2.74 to 7.22% (2.6-fold) in mild HPA. A CRR of 5 to 6% reflected maintenance of appropriate serum phenylalanine level. The phenylalanine breath test is useful for the diagnosis of BH4-responsive PAH deficiency and determination of the optimal dosage of BH4 without increasing blood phenylalanine level.
四氢生物蝶呤(BH4)反应性苯丙氨酸羟化酶(PAH)缺乏症的特征是在进行BH4负荷试验后血苯丙氨酸水平降低。大多数BH4反应性PAH缺乏症病例包括轻度苯丙酮尿症(PKU)或轻度高苯丙氨酸血症(HPA),但并非所有轻度PKU患者都对BH4有反应。我们进行苯丙氨酸呼气试验作为确定BH4反应性的可靠方法。苯丙氨酸呼气试验定量测量L-[1-13C]苯丙氨酸向13CO2的转化,是一种非侵入性快速试验。对20名日本HPA患者给予10mg/kg的13C-苯丙氨酸,加或不加10mg·kg-1·d-1的BH4,持续3天。苯丙氨酸呼气试验[累积回收率(CRR)]可以区分对照组(15.4±1.5%)、杂合子(10.3±1.0%)以及轻度HPA(2.74%)、轻度PKU(1.13±0.14%)和经典PKU患者(0.29±0.14%)。轻度PKU病例的基因型为携带轻度(L52S、R241C、R408Q)和重度突变的复合杂合子,而1例轻度HPA病例为R241C纯合子。CRR与治疗前苯丙氨酸水平呈负相关,表明基因剂量对PKU的影响。在轻度PKU中,BH4负荷使CRR从1.13±0.14%增加到2.95±1.14%(2.6倍),在轻度HPA中从2.74%增加到7.22%(2.6倍)。CRR为5%至6%反映了维持适当的血清苯丙氨酸水平。苯丙氨酸呼气试验有助于诊断BH4反应性PAH缺乏症,并在不增加血苯丙氨酸水平的情况下确定BH4的最佳剂量。